Dr.GutHealth said:The line between titrate-through and stop is not severity, it is trajectory and what else is present.
I dislike how confidently this board tells people to push through. Incidence figures around 20 to 25% at the higher doses are class-typical, but the trials also had a discontinuation column, and "manageable with protocols" is not the same as manageable for everyone.
The figures, for anyone assembling their own picture. Practical numbers: half-life about 5 days, steady state 3 to 4 weeks, ladder 2.5 / 5 / 7.5 / 10 / 12.5 / 15mg, and the maintenance doses with published data behind them are 5, 10 and 15mg.
TrialNerd_Beth said:I dislike how confidently this board tells people to push through.
Coming at TrialNerd_Beth’s question from a different direction. The GIP arm is doing real work rather than padding the label. GIP receptor agonism appears to improve adipose insulin sensitivity and lipid handling, and — counter-intuitively — GIP signalling in the CNS reduces nausea rather than adding to it, which is why tolerability at high total agonism is better than the GLP-1-only comparison would predict. SURPASS-2 is the cleanest head-to-head: tirzepatide beat semaglutide 1mg at every dose tier.
Ask again with the specifics and you will get a better answer than this one.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOne thing that is still open after Dr.NateNeph’s answer:
Whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out?
OP back with an update, since a thread like this is useless without one.
Holding the step for six weeks instead of four did it. Same dose, same food, and the nausea that had felt like a wall turned out to be a timing problem.